Back to mobile site

Citi Defends Integra LifeSciences (IART); Says Sell-Off Overdone

January 9, 2012 12:35 PM EST
Get Alerts IART Hot Sheet
Price: $17.69 --0%

Rating Summary:
    9 Buy, 15 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 3 | Down: 6 | New: 25
Join SI Premium – FREE
Citi's Amit Bhalla is defending Buy-rated Integra LifeSciences (Nasdaq: IART) Monday morning following Friday's 19.7 percent sell-off amid a Q4 warning and FDA letter on its Plainsborough, NJ plant.

Bhalla calls last week's sharp decline "overdone" and said he feels Integra should be able to clean up its company-specific issues in the first half of 2012, but sees macro headwinds lingering.

Bhalla reiterates his $33 price target on the stock.

On the other side of the trade Monday, Argus Research's David Toung downgraded the stock from Buy to Hold earlier.

The Argus downgrade seems to be weighing on shares of Integra Monday: the stock last traded at $24.20, down 1.2 percent from Friday's closing price.

Visit our Analyst Ratings page to track all the market-moving analyst action on shares of Integra.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments

Related Entities

Citi, Argus